EYEN News and Press, Eyenovia Inc. From 03/23/23

NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indica...

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progress...

Summary I will update my previous two articles about Eyenovia. NDA accepted with no outside advisory committee formed to review their submission. FDA decision date for the NDA set for May 8, 2023. Eyenovia secures first outside drug company partnership potential for using their ...

NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progress...

Formosa Pharmaceuticals on Wednesday has entered into a collaboration agreement with Eyenovia ( NASDAQ: EYEN ) for the development of novel ophthalmic therapeutics. The integration will combine Formosa's proprietary APNT™ nanoparticle formulation platform with Eyenovia's&#x...

Eyenovia ( NASDAQ: EYEN ) is trading ~5% higher premarket after it announced positive results from a research study that showed Optejet delivery technology decreased inflammation from preserved glaucoma solutions sompared to drops. The study evaluated the gene and protein expr...

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric prog...

Booth to feature “smart” remote patient monitoring capabilities being developed for future versions of the company’s novel Optejet® drug delivery technology Company to occupy booth 8311 NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDA...

Eyenovia ( NASDAQ: EYEN ) stock rose ~4% on Tuesday after the company said the U.S. Food and Drug Administration (FDA) accepted for review its resubmitted application seeking approval of MydCombi ophthalmic spray. Eyenovia noted that MydCombi is a drug-device combination ...

Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel Optejet ® drug delivery technology Company also announced receipt of California Medical Device Manufacturing license NEW...